Publications

Selected publications authored or co-authored by the founders and employees of WILEX:

Ringhoffer M., Muller C. R., Schenk A., Kirsche H., Schmitt M., Greiner J., and Gschwend J. E. Simultaneous expression of T-cell activating antigens in renal cell carcinoma: implications for specific immunotherapy. In: J.Urol. 171 (6 Pt 1):2456-2460, 2004.

Luther T., Kotzsch M., Meye A., Langerholc T., Fussel S., Olbricht N., Albrecht S., Ockert D., Muehlenweg B., Friedrich K., Grosser M., Schmitt M., Baretton G., and Magdolen V. Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. In: Thromb.Haemost. 89 (4):705-717, 2003.

Schmitt M., Magdolen V., and Reuning U. Theme Issue: Update on the role of the fibrinolysis/plasminogen activation system in a cellular context. In: Thromb.Haemost. 89 (4): 596-598, 2003.

Schuh T., Besch R., Braungart E., Flaig M. J., Douwes K., Sander C. A., Magdolen V., Probst C., Wosikowski K., and Degitz K. Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis. In: Biol.Chem. 384 (2):311-315, 2003.

Reuning U., Sperl S., Kopitz C., Kessler H., Kruger A., Schmitt M., and Magdolen V. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. In: Curr.Pharm.Des 9 (19):1529-1543, 2003.

Krol J., Sato S., Rettenberger P., Assfalg-Machleidt I., Schmitt M., Magdolen V., and Magdolen U. Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems. In: Biol.Chem. 384 (7):1085-1096, 2003.

Krol J., Kopitz C., Kirschenhofer A., Schmitt M., Magdolen U., Kruger A., and Magdolen V. Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems. In: Biol.Chem. 384 (7):1097-1102, 2003.

Reuning U., Magdolen V., Hapke S., and Schmitt M. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins. In: Biol.Chem. 384 (8):1119-1131, 2003.

Zemzoum I., Kates R. E., Ross J. S., Dettmar P., Dutta M., Henrichs C., Yurdseven S., Hofler H., Kiechle M., Schmitt M., and Harbeck N. Invasion Factors uPA/PAI-1 and HER2 Status Provide Independent and Complementary Information on Patient Outcome in Node-Negative Breast. In: Cancer J.Clin.Oncol. 21 (6):1022-1028, 2003.

Look M., Van Putten W., Duffy M., Harbeck N., Christensen I. J., Thomssen C., Kates R., Spyratos F., Ferno M., Eppenberger-Castori S., Fred Sweep C. G., Ulm K., Peyrat J. P., Martin P. M., Magdelenat H., Brunner N., Duggan C., Lisboa B. W., Bendah P. O., Quillien V., Daver A., Ricolleau G., Meijer-Van Gelder M., Manders P., Edward F. W., Blankenstein M., Broet P., Romain S., Daxenbichler G., Windbichler G., Cufer T., Borstnar S., Kueng W., Beex L., Klijn J., O'Higgins N., Eppenberger U., Janicke F., Schmitt M., and Foekens J. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. In: Thromb.Haemost. 90 (3):538-548, 2003.

Sweep F. C., Fritsche H. A., Gion M., Klee G. G., and Schmitt M. Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report. Int.J.Oncol. 23 (6):1715-1726, 2003.

Guthaus E., Schmiedeberg N., Buergle M., Magdolen V., Kessler H., Schmitt M. The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction. In: Recent Results in Cancer Research, Vol. 162, 2003

Magdolen V., Krueger A., Sato S., Nagel J., Sperl S., Reuning U., Rettenberger P., Magdolen U., Schmitt M. Inhibition of the tumor associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. In: Recent Results in Cancer Research, Vol. 162, 2003

Harbeck N., Kates R.E., Look M.P., Meijer-van Gelder M.E., Klijn J.G.M., Krüger A., Kiechle M., Jänicke F., Schmitt M., Foekens J.A. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). In: Cancer Research 62, 4617-4622, August 15, 2002.

Magdolen U., Krol J., Sato S., Mueller M.M., Sperl S., Krueger A., Schmitt M., Magdolen V. Natural inhibitors of tumor-associated proteases. Radiol Oncol 2002; 36(2): 131-143.

Buergle M., Sperl S., Stürzebecher J., Krüger A., Schmalix W., Kessler H., Moroder L., Magdolen V., Wilhelm O.G., Schmitt M. The urokinase-type plasminogen activator (uPA) system: a new target for tumor therapy. In: Smith H.J., Simons C. (editors), Proteinase and peptidase inhibition – recent potential targets for drug development. London, 2002, pp. 231-248.

Guthaus E., Buergle M., Schmiedeberg N., Hocke S., Eickler A., Kramer M.D., Sweep C.G., Magdolen V., Kessler H., Schmitt M. uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics. Biol Chem. 2002 Jan; 383(1): 207-16.

Arroyo de Prada N., Schroeck F., Sinner E., Muehlenweg B., Twellmeyer J., Sperl S., Wilhelm O.G., Schmitt M. and Magdolen V. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin. Eur. J. Biochem. 269, 184-192, 2002

Magdolen V., Buergle M., Arroyo de Prada N., Schmiedeberg N., Riemer C., Schroek F., Kellermann J., Degitz K., Wilhelm O.G., Schmitt M. and Kessler H. Cyclo19,31[D-Cys19]-uPA19-31 Is a Potent Competitive Antagonist of the Interaction of Urokinase-Typ Plasminogen Activator with Its Receptor [CD87). Biol.Chem., Vol. 382, pp. 1197-1205, 2001

Muehlenweg B., Sperl S., Magdolen V., Schmitt M., Harbeck N. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opin. Biol. Ther., 1, 683-691, 2001

Lutz V., Reuning U., Krueger A., Luther T., Pildner von Steinburg S., Graeff H., Schmitt M., Wilhelm O.G. and Magdolen V. High level synthesis of recombinant soluble Urokinase Receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol. Chem; 382, 789-798, 2001

Sperl S., Mueller M.M., Wilhelm O.G., Schmitt M., Magdolen V. and Moroder L.. The uPA/uPA Receptor System as a Target for Tumor Therapy. Drug News Perspect 14 (7), 401-411, Sept. 2001.

Jaenicke F., Prechtl A., Thomssen C., Harbeck N., Meisner C., Untch M., Sweep C.G.J.F., Selbmann H-K., Graeff H., Schmitt M. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Journal of the National Cancer Institute, Vol. 93, No. 12, June 20, 2001.

Kotzsch M., Luther T., Harbeck N., Ockert D., Lutz V., Noack F., Grossmann D., Albrecht S., Kramer M.D., Lossnitzer A., Grosser M., Schmitt M., Magdolen V. New ELISA for quantitation of human urokinase receptor (CD87) in cancer. Int J Oncol. 2000 Oct;17(4):827-34.

Hildenbrand R., Leitz M., Magdolen V., Luther T., Albrecht S., Graeff H., Stutte H.J., Bleyl U., Schmitt M. Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization. Histopathology. 2000 Jun;36(6):499-504.

Magdolen V., de Prada N.A., Sperl S., Muehlenweg B., Luther T., Wilhelm O.G., Magdolen U., Graeff H., Reuning U., Schmitt M. Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator. Adv Exp Med Biol; 477, 331-341, 2000.

Schmitt M., Wilhelm O.G., Reuning U., Krueger A., Harbeck N., Lengyel E., Graeff H., Gaensbacher B., Kessler H., Buergle M., Stuerzebecher J., Sperl S., Magdolen V. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis & Proteolysis, 14, 114-132, 2000.

Muehlenweg B., Assfalg-Machleidt I., Parrado S.G., Buergle M., Creutzburg S., Schmitt M., Auerswald E.A., Machleidt W., Magdolen V. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site. J Biol Chem; 275 (43), 33562-33566, 2000.

Magdolen V., de Prada N.A., Sperl S., Muehlenweg B., Luther T., Wilhelm O.G., Magdolen U., Graeff H., Reuning U., Schmitt M. Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator. Adv Exp Med Biol; 477, 331-341, 2000.

Sperl S., Jakob U., Arroyo de Prada N., Stuerzebecher J., Wilhelm O., Bode W., Magdolen V., Huber R., Moroder L. (2000) (4-Aminomethyl) phenylguanidine derivates as nonpeptidic highly selective inhibitors of human urokinase.  Proc Nat Acad Sci USA97, 5113-8.

Muehlenweg B., Guthaus E., Arroyo de Prada N., Schmitt M., Schmiedeberg N., Kotzsch M., Creutzburg S., Kramer MD., Kessler H., Wilhelm O.G. and Magdolen V. (2000) Epitope Mapping of Monoclonal Antibodies Directed to PAI-1 Using PAI-1/PAI-2 Chimera and PAI-1-Derived Synthetic Peptides.  Thrombosis Research 98, 73-81.

Krueger A., Soeltl R., Lutz V., Wilhelm O.G., Magdolen V., Rojo E.E., Hantzopoulus P.A., Graeff H., Gaensbacher B. and Schmitt M. (2000) Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor.  Cancer Gene Therapy (2), 292-9.

Wilhelm O.G., Wilhelm S., Escott G.M., Lutz V., Magdolen V., Schmitt M., Rifkin D.B., Wilson E.L., Graeff H., Brunner G. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol. 1999 Aug;180(2):225-35.

Stephens R.W., Bruenner N., Jaenicke F. and Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Research and Treatment (1999), in press

Schmitt M., Kuhn W., Harbeck N. and Graeff H. Thrombophilic state in breast cancer. Seminars in Thrombosis and Hemostasis (1999), in press

Kuhn W., Schmalfeldt B., Reuning U., Berger U., Pache L., Ulm K., Hoefler H., Jaenicke F., Schmitt M. and Graeff H. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. British Journal of Cancer (1999), in press

Harbeck N., Thomssen C., Berger U., Ulm K., Hoefler H., Jaenicke F., Graeff H. and Schmitt M. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-uPAR both for primary breast cancer and following first relapse. Breast Cancer Research and Treatment (1999), in press

Harbeck N., Dettmar P., Thomssen C., Berger U., Ulm K., Hoefler H., Jaenicke F., Graeff H. and Schmitt M. Tumor invasion marker PAI-1, a strong predictor of survival in node-negative breast cancer at six-year median follow-up. British Journal of Cancer (1999), in press

Reuning U., Guerrini L., Nishiguchi T., Seibold H., Page S., Magdolen V. , Graeff H. and Schmitt M. REL-transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells. European Journal of Biochemistry 259:143-148, 1999

Wilhelm S., Schmitt M. , Parkinson J., Kuhn W., Graeff H. and Wilhelm O. Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO III. International Journal of Oncology>13:645-651, 1998

Thomssen C., Oppelt P., Jaenicke F., Ulm K., Harbeck N., Hoefler H., Kuhn W., Graeff H. and Schmitt M. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Research 18:2173-2180, 1998

Sweep C.G.J., Geurts-Moespot J, Grebenschikov N., de Witte J.H., Heuvel J.J.T.M., Schmitt M., Duffy M.J., Jaenicke F., Kramer M.D., Foekens J.A., Brünner N., Brugal G., Pedersen A. and Benraad T.J. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer extracts. British Journal of Cancer 78:1434-1441, 1998

Ruiter D.J., Ferrier C.M., van Muijen G.M.P., Henzen-Logmans S.C., Kennedy S., Kramer M.D., Sehested M. and Schmitt M. Quality control of immunohistochemical evaluation of tumor-associated plasminogen activators and related components. European Journal of Cancer 34:1334-1340, 1998

Reuning U., Magdolen V. , Wilhelm O.G., Fischer K., Lutz V., Graeff H. and Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. International Journal of Oncology 13:893-906, 1998

Nekarka H., Schlegel P., Schmitt M. , Stark M., Mueller J.D., Fink U. and Siewert J.R. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clinical Cancer Research 4:1755-1763, 1998

Magdolen V. , Albrecht S., Kotzsch M., Haller C., Buergle M., Jacob U., Großer M., Graeff H., Mueller M., Schmitt M. and Luther T. Immunological and functional analyses of the extracellular domain of human tissue factor. Biological Chemistry 379:157-165, 1998

Hildenbrand R., Glienke W., Magdolen V. , Berger S., Hoerlin A., Graeff H., Stutte H.J. and Schmitt M. Urokinase receptor (CD87) m-RNA and protein dection in human breast cancer by both in situ hybridization and immunohistochemistry. Histochemistry and Cell Biology 110:27-32, 1998

Harbeck N., Dettmar P., Thomssen C., Henselmann B., Kuhn W., Ulm K., Jaenicke F., Hoefler H., Graeff H. and Schmitt M. Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Research 18:2187-2198, 1998

Fischer K., Lutz V., Wilhelm O.G., Schmitt M. , Graeff H., Heiss P., Nishiguchi T., Harbeck N., Kessler H., Luther T., Magdolen V. and Reuning U. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS-Letters 438:101-105, 1998

Eppenberger U., Kueng W., Schlaeppi J.-M., Roesel J.L., Benz C., Mueller H., Matter A., Zuber M., Luescher K., Litschgi M., Schmitt M. , Foekens J.A. and Eppenberger-Castori S. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. Journal of Clinical Oncology 16:3129-3136, 1998

Schmitt M. , Harbeck N., Thomssen C., Wilhelm O.G., Magdolen V., Reuning U., Ulm K., Hoefler H., Jaenicke F. and Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy.Thrombosis and Hemostasis 78:285-296, 1997

Schmitt M. , Thomssen C., Ulm K., Seiderer A., Hoefler H., Jaenicke F. and Graeff H. Time-varying prognostic impact of tumor biological factors urokinase (uPA) and PAI-1 in breast cancer. British Journal of Cancer 76:306-311, 1997

Luther T., Magdolen V. , Albrecht S., Lopens A., Kasper M., Riemer C., Kessler H., Mueller M. and Schmitt M. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am. J. Pathology 150:1231-1244, 1997

Laugwitz K.-L., Kronsbein K. Schmitt M., Hoffmann K., Seyfahrt M., Schoemig A. and Ungerer M. Characterization and inhibition of ß-adrenergic receptor kinase in intact myocytes. Cardiovascular Research 35:324-333, 1997

Koehler U., Hiller K., Martin R., Langanke D., Naumann G., Bilek K., Jaenicke F. and Schmitt M. Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma. Gynecologic Oncology 66:268-274, 1997

Goretzki L., Bognacki J., Koppitz M., Rettenberger P., Magdolen V. , Creutzburg S., Hammelburger J., Weidle U., Wilhelm O.G., Kessler H., Graeff H., Schmitt M. Quantitative assessment of interaction of urokinase-type plasminogen activator and its receptor (CD87) by use of a solid-phase uPA-ligand binding assay. Fibrinolysis & Proteolysis 11, 11-19, 1997

Dettmar P., Harbeck N., Thomssen C., Pache L., Ziffer P., Fizi K., Jänicke F., Nathrath W., Schmitt M., Graeff H. and Höfler H. Prognostic impact of proliferation-associated factors MIB1(Ki-67) and S-phase in node-negative breast cancer. British Journal of Cancer 75:1525-1533, 1997

Buergle M., Koppitz M., Riemer C., Kessler H., Koenig B., Weidle U., Kellermann J., Lottspeich F., Graeff H., Schmitt M., Goretzki L., Reuning U., Wilhelm O.G., Magdolen V. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biological Chemistry Hoppe Seyler 378:231-237, 1997

Wagner S., Atkinson M., Wagner C., Hoefler H , Schmitt M. and Wilhelm O.G. Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney. Histochem. Cell Biology 105, 53-60, 1996

Wagner S., Atkinson M., Thanner S., Schmitt M., Wilhelm O.G., Rotter M. and Hoefler H. Type-1 plasminogen activator inhibitor in human renal cell carcinoma. J. of Pathology ,179, 95-99, 1996

Thomssen C., Oppelt P., Jaenicke F., Ulm K., Harbeck N., Hoefler H., Graeff H. and Schmitt M. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Research, 1996

Schmitt M. , Thomssen C., Jaenicke F., Hoefler H., Ulm K., Magdolen V., Reuning U., Wilhelm O.G. and Graeff H. Clinical significance of the serine protease uPA (urokinase) and its inhibitor PAI-1 as well as the cysteine proteases cathepsin B and L in breast cancer. In: Breast Cancer. Advances in biology and therapeutics. (Calvo, Crepin, Magdelenat, eds.) pp. 191-200, 1996.

Ott I., Neumann F.J., Gawaz M., Schmitt M. and Schoemig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 94:1239-1246, 1996

Magdolen V. , Rettenberger P., Koppitz M., Goretzki L., Kessler H., Graeff H., Schmitt M. and Wilhelm O.G. Systematic mutational analysis of the receptor binding region of the human urokinase-type plasminogen activator (uPA). Eur. J. Biochemistry, 237, 743-751, 1996

Kanse S., Kost C., Wilhelm O.G., Andreasen P. and Preissner K. Characterization of urokinase-receptor as a major vitronectin binding protein on endothelial cells: modulation by urokinase and plasminogen activator inhibitor-1. Exp. Cell Res., 224, 344-353, 1996

Benraad T.J., Geurts-Moespot, J., Grondahl-Hansen J., Schmitt M., Heuvel J.J.T.M., de Witte J.H., Foekens J.A., Leake R.E., Bruenner N. and Sweep C.G.J. Immunoassays (Elisa) of urokinase-type plasminogen activator system. Report of an EORTC/BIOMED-1 workshop. European Journal of Cancer 32A:1371-1381, 1996

Wilhelm O.G., Schmitt M. , Hoehl S., Senekowitsch R. and Graeff H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin. Exp. Metastasis 13, 296-302, 1995

Wagner S., Atkinson M., Thanner S., Wagner Ch., Schmitt M., Wilhelm O.G., Rotter M. and Hoefler H. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am. J. Pathology 147, 183-192, 1995

Triebel S., Blaeser J., Gote T., Pelz G., Schueren E., Schmitt M. and Tschesche H. Evidence for the tissue inhibitor of metalloproteinases-1 (TIMP-1) in human polymorphonuclear leukocytes. European Journal of Biochemistry 231: 714-719, 1995

Thomssen Ch., Schmitt M. , Goretzki L., Oppelt P., Pache L., Dettmar P., Jaenicke F. and Graeff H. Prognostic value of the cysteine proteases cathepsin B and cathepsin L in human breast cancer. Clinical Cancer Research 1: 741-746, 1995

Schmitt M. , Wilhelm O.W., Jaenicke F., Magdolen V. , Reuning U., Ohi H., Moniwa N., Kobayashi H., Weidle U., and Graeff H. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. J. Obstet. Gynecol. 21, 151-165, 1995.

Schmalfeldt B., Kuhn W., Reuning U., Pache L., Dettmar P., Schmitt M., Jaenicke F., Hoefler H. and Graeff H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator (uPA), its receptor (uPA-R) and inhibitors type-1 (PAI-1) and type-2 (PAI-2). Cancer Research 55:3958-3963, 1995

Reuning U., Wilhelm O.G., Nishigushi T., Guerini L., Blasi F., Graeff H. and Schmitt M. Inhibition of NFk B-Rel A expression by "antisense" oligonucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1. Nucl. Acids Res., 23, 3887-3893, 1995

Rettenberger P., Wilhelm O.G., Oi H., Weidle U., Goretzki L., Koppitz M., Lottspeich F., Koenig B., Pessara U., Kramer M., Schmitt M. and Magdolen V. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor. Biological Chemistry Hoppe Seyler , 376, 587-594, 1995.

Magdolen V., Rettenberger P., Lopens A., Oi H., Lottspeich F., Kellermann J., Creutzburg S., Goretzki L., Weidle U., Wilhelm O.G., Schmitt M. and Graeff H. Expression of the human uPA receptor (uPAR) in E. coli and CHO cells: Purification of the recombinant proteins and generation of polyclonal antibodies in chicken. Electrophoresis 16, 813-816, 1995

Harbeck N., Schwarze S., Schueren E., Yamamoto N., Moniwa N., Schmitt M., Dettmar P., Nathrath W., Jaenicke F., Hoefler H. and Graeff H. Model system for isolation of competent ovarian carcinoma cells from fresh tumor tissue by a magnetic separation technique (MACS). International Journal of Oncology 6: 1249-1254, 1995

Will C., Wilhelm O.G., Moebus V., Weidle U., Kreienberg R., Jaenicke F., Schmitt M. and Graeff H. Expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human ovarian cancer cells and in vitro invasion capacity. International Journal of Oncology 5: 753-761, 1994>

Wilhelm O.G., Weidle U., Hoehl S., Rettenberger P., Schmitt M. and Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA) : Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett. 337, 131-134, 1994

Nekarda H., Siewert J.R., Schmitt M. and Ulm K. Tumor-associated proteolytic factors uPA and PAI-1and survival in totally resected gastric cancer. The Lancet 343, January 8, p. 117, 1994

Nekarda H., Schmitt M., Ulm K., Wenninger A., Vogelsang H., Becker K., Roder J.D., Fink U. and Siewert J.R. Prognostic impact of urokinase-type plasminogen activator uPA and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Research 54: 2900-2907, 1994

McGahon A., Bissonnette R., Schmitt M., Cotter K.M., Green D.R. and Cotter T.G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83: 1179-1187, 1994

Kuhn W., Pache L., Schmalfeld B., Dettmar P., Schmitt M., Jaenicke F. and Graeff H. Urokinase (uPA) and PAI-1 Predict Survival in Advanced Ovarian Cancer Patients (FIGO III) after Radical Surgery and Platinum-based Chemotherapy. Gynecologic Oncology 55: 401-409, 1994

Jaenicke F., Pache L., Schmitt M., Ulm K., Thomssen C., Prechtl A. and Graeff H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1. Cancer Research 54: 2527-2530, 1994

Foekens J.A., Schmitt M., van Putten W.L.J., Peters H.A., Jaenicke F. and Klijn J.M.G. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. Journal of Clinical Oncology 12: 1648-1658, 1994

Pedersen N., Schmitt M., Ronne E., Nicolettic M.I., Hoyer-Hansen G., Conese M., Giavazzi R., Dano K., Kuhn W., Jaenicke F. and Blasi F. A ligand-free, soluble urokinase-receptor is present in the ascitic fluid from patients with ovarian cancer. Journal of Clinical Investigation 92:2160-2167, 1993

Kobayashi H., Ohi H., Shinohara H., Sugimura M., Fujii T., Terao T., Schmitt M., Goretzki L., Chucholowski N., Jaenicke F. and Graeff H. Saturation of tumor cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. British Journal of Cancer 67:537-544, 1993

Berdel W., Wilhelm O.G., Maurer J., Schmitt M., Reufi B., von Marschall Z., Oberberg D., Graeff H. and Thiel E. Urokinase-type plasminogen activator (uPA), a protease with cytokine-like activity in human HL-60 leukemic cell line. Int. J. Oncology 3, 607-613, 1993

Schmitt M., Jaenicke F. and Graeff H. Tumor-associated proteases. Fibrinolysis 6, Suppl. 4:3-26, 1992

Jaenicke F., Schmitt M., Pache L., Ulm K., Harbeck N., Hoefler H. and Graeff H. Urokinase (uPA) is a strong independent prognostic factor in node-negative breast cancer. Breast Cancer Research and Treatment 24:195-208, 1992

Goretzki L., Schmitt M., Mann K.-H., Calvete J., Chucholowski N., Kramer M., Guenzler W.A., Jaenicke F. and Graeff H. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS-Letters 297:112-118, 1992

Foekens J.A., Schmitt M., van Putten W.L.J., Peters H.A., Bontenbal M., Jaenicke F. and Klijn J.G.M. Prognostic value of urokinase-type plasminogen activator (uPA) in 671 primary breast cancer patients. Cancer Research 52: 6101-6105, 1992

Sier C.F.M., Fellbaum C., Verspaget H.W., Schmitt M., Griffioen G., Graeff H., Hoefler H. and Lamers C.B.H.W. Immunolocalization of urokinase-type plasminogen activator (uPA) in adenomas and carcinomas of the human colon. Histopathology 19:231-237, 1991

Schmitt M., Chucholowski N., Goretzki L., Busch E., Hellmann D., Wagner B., Jaenicke F. and Graeff H. Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator (uPA) on tumor cells. Seminars in Thrombosis and Haemostasis 17:291-302, 1991

Kobayashi H., Schmitt M., Goretzki L., Chucholowski N., Calvete J., Kramer M., Guenzler W.A., Jaenicke F. and Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). Journal of Biological Chemistry 266: 5147-5152, 1991

Jaenicke F., Schmitt M. and Graeff H. Prognostic relevance of plasminogen activator uPA, its inhibitor PAI-1 and cathepsin D in breast cancer. Seminars in Thrombosis and Hemostasis 17:303-312, 1991

Wilhelm O.G., Jaskunas R., Vlahos C. and Bang N.U. Functional properties of the kringle-2 domain of tissue plasminogen activator produced in E. coli. J. Biol. Chem. 265, 15606-14611, 1990

Wilhelm O.G., Hafter R., Henschen A., Schmitt M. and Graeff H. Essential role of thrombin and plasmin in the degradation of the provisional tumor stroma in human ovarian carcinoma. Blood 75(8), 1673-1678, 1990

Jaenicke F., Schmitt M., Ulm K., Goessner W. and Graeff H. The urokinase-type plasminogen activator (uPA) antigen is related to early relapse in breast cancer. The Lancet, Volume II, 28 October, No 8670, 1049, 1989

Wilhelm O.G., Hafter R., Coppenrath E., Pflanz M.A., Schmitt M., Babic R., Linke R., Goessner R. and Graeff H. Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. Cancer Res. 48, 3507-3514, 1988